The ranking is based on Census data. Facebook / City of Bellaire, Texas

Affluent Houston neighbor Bellaire is cashing in as the richest small town in Texas for 2025, according to new study from GoBankingRates.

The report, "The Richest Small Town in Every State," used data from the U.S. Census Bureau's American Community Survey to determine the 50 richest small towns in America based on their median household income.

Of course, Houstonians realize that describing Bellaire as a "small town" is a bit of misnomer. Located less than 10 miles from downtown and fully surrounded by the City of Houston, Bellaire is a wealthy enclave that boasts a population of just over 17,000 residents. These affluent citizens earn a median $236,311 in income every year, which GoBankingRates says is the 11th highest household median income out of all 50 cities included in the report.

The average home in this city is worth over $1.12 million, but Bellaire's lavish residential reputation often attracts properties with multimillion-dollar price tags.

Bellaire also earned a shining 81 livability score for its top quality schools, health and safety, commute times, and more. The livability index, provided by Toronto, Canada-based data analytics and real estate platform AreaVibes, said Bellaire has "an abundance of exceptional local amenities."

"Among these are conveniently located grocery stores, charming coffee shops, diverse dining options and plenty of spacious parks," AreaVibes said. "These local amenities contribute significantly to its overall appeal, ensuring that [residents'] daily needs are met and offering ample opportunities for leisure and recreation."

Earlier in 2025, GoBankingRates ranked Bellaire as the No. 23 wealthiest suburb in America, and it's no stranger to being named on similar lists comparing the richest American cities.

---

This article originally appeared on CultureMap.com.

Here's how Texas towns stacked up on a new population report. Photo via Getty Images

Booming Houston suburb, other Texas towns among the fastest-growing U.S. cities in 2023

by the numbers

One Houston suburb experienced one of the most rapid growth spurts in the country last year: Fulshear, whose population grew by 25.6 percent, more than 51 times that of the nation’s growth rate of 0.5 percent. The city's population was 42,616 as of July 1, 2023.

According to U.S. Census Bureau's Vintage 2023 Population Estimates, released Thursday, May 16, Fulshear — which lies west of Katy in northwest Fort Bend County - ranked No. 2 on the list of fastest-growing cities with a population of 20,000 or more. It's no wonder iconic Houston restaurants like Molina's Cantina see opportunities there.

The South still dominates the nation's growth, even as America’s Northeast and Midwest cities are rebounding slightly from years of population drops. The census estimates showed 13 of the 15 fastest-growing cities in the U.S. were in the South — eight in Texas alone.

The Texas cities joining Fulshear on the fastest-growing-cities list are:

  • Celina (No. 1) with 26.6 percent growth (42,616 total population)
  • Princeton (No. 3) with 22.3 percent growth (28,027 total population)
  • Anna (No. 4) with 16.9 percent growth (27,501 total population)
  • Georgetown (No. 8) with 10.6 percent growth (96,312 total population)
  • Prosper (No. 9) with 10.5 percent growth (41,660 total population)
  • Forney (No. 10) with 10.4 percent growth (35,470 total population)
  • Kyle (No. 11) with 9 percent growth (62,548 total population)

Texas trends
San Antonio saw the biggest growth spurt in the United States last year, numbers-wise. The Alamo City added about 22,000 residents. San Antonio now has nearly 1.5 million people, making it the the seventh largest city in the U.S. and second largest in Texas.

Its population boom was followed by those of other Southern cities, including Fort Worth; Charlotte, North Carolina; Jacksonville, Florida; and Port St. Lucie, Florida.

Fast-growing Fort Worth (978,000) surpassed San Jose, California (970,000) to become the 12th most populous city in the country.

Meanwhile, population slowed in the Austin area. Jacksonville, Florida (986,000), outpaced Austin (980,000), pushing the Texas capital to 11th largest city in the U.S. (barely ahead of Fort Worth).

Population growth in Georgetown, outside Austin, slowed by more than one-fourth its population growth in 2022, the report says, from 14.4 percent to 10.6 percent. It's the same story in the Central Texas city of Kyle, whose population growth decreased by nearly 2 percent to 9 percent in 2023.

Most populated cities
New York City with nearly 8.3 million people remained the nation's largest city in population as of July 1, 2023. Los Angeles was second at close to 4 million residents, while Chicago was third at 2.7 million and Houston was fourth at 2.3 million residents.

The 15 populous U.S. cities in 2023 were:

  1. New York, New York (8.3 million)
  2. Los Angeles, California (4 million)
  3. Chicago, Illinois (2.7 million)
  4. Houston, Texas (2.3 million)
  5. Phoenix, Arizona (1.7 million)
  6. Philadelphia, Pennsylvania (1.6 million)
  7. San Antonio (1.5 million)
  8. San Diego, California (1.4 million)
  9. Dallas (1.3 million)
  10. Jacksonville, Florida (986,000)
  11. Austin (980,000)
  12. Fort Worth (978,000)
  13. San Jose (970,000)
  14. Columbus, Ohio (913,000)
  15. Charlotte, North Carolina (911,000)

Modest reversals of population declines were seen last year in large cities in the nation's Northeast and Midwest. Detroit, for example, which grew for the first time in decades, had seen an exodus of people since the 1950s. Yet the estimates released Thursday show the population of Michigan’s largest city rose by just 1,852 people from 631,366 in 2022 to 633,218 last year.

It's a milestone for Detroit, which had 1.8 million residents in the 1950s only to see its population dwindle and then plummet through suburban white flight, a 1967 race riot, the migration to the suburbs by many of the Black middle class and the national economic downturn that foreshadowed the city's 2013 bankruptcy filing.

Three of the largest cities in the U.S. that had been bleeding residents this decade staunched those departures somewhat. New York City, which has lost almost 550,000 residents this decade so far, saw a drop of only 77,000 residents last year, about three-fifths the numbers from the previous year.

Los Angeles lost only 1,800 people last year, following a decline in the 2020s of almost 78,000 residents. Chicago, which has lost almost 82,000 people this decade, only had a population drop of 8,200 residents last year.

And San Francisco, which has lost a greater share of residents this decade than any other big city — almost 7.5 percent — actually grew by more than 1,200 residents last year.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”